Old biliverdin reductase: links to insulin resistance and may be a novel therapeutic target

Related Experiment Video

Updated: Jul 6, 2026

Precise Visualization of Insulin Receptors A and B in Murine Brain with an RNA In Situ Hybridization Assay
08:34

Precise Visualization of Insulin Receptors A and B in Murine Brain with an RNA In Situ Hybridization Assay

Published on: July 15, 2025

Bin Wu1, Xiaoyan Liu, Jinfang Shen

  • 1Division of Clinical Pharmacy, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University, China.

Medical Hypotheses
|April 9, 2008
PubMed

Insights

BVR, an antioxidant enzyme, shows potential in treating insulin resistance by scavenging reactive oxygen species (ROS) and modulating key molecules like IRS-1 and PI3K, offering a new therapeutic target for type 2 diabetes.

Area of Science:

  • Biochemistry
  • Metabolic Diseases
  • Enzymology

Background:

  • Insulin resistance is central to type 2 diabetes and metabolic diseases, but its molecular mechanisms remain unclear.
  • Reactive oxygen species (ROS), IRS-1, and PI3K are implicated in insulin resistance development.
  • Current treatments for insulin resistance are limited.

Purpose of the Study:

  • To investigate the role of biliverdin reductase (BVR) in the progression of insulin resistance.
  • To explore BVR's potential as a therapeutic target for insulin resistance.

Main Methods:

  • Review of existing research on BVR's enzymatic and non-enzymatic functions.
  • Analysis of BVR's interaction with ROS, IRS-1, and PI3K pathways.

Main Results:

  • BVR acts as a potent antioxidant, neutralizing excess ROS.
  • BVR possesses kinase activity and binds to p85, influencing IRS-1 and PI3K functions.
  • These actions suggest BVR can ameliorate insulin resistance.

Conclusions:

  • BVR plays a significant role in insulin resistance progression.
  • BVR represents a promising therapeutic target for managing insulin resistance and related metabolic disorders.

Related Concept Videos

Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...